HC Wainwright & Co. Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $9

Cardiol Therapeutics Inc Ordinary Shares - Class A +1.65% Pre

Cardiol Therapeutics Inc Ordinary Shares - Class A

CRDL

1.23

1.23

+1.65%

0.00% Pre

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Cardiol Therapeutics (NASDAQ: CRDL) with a Buy rating and announces Price Target of $9.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via